On September 24, 2020, Monte Rosa Therapeutics, a biotechnology company developing precision medicines to degrade disease-causing proteins, announced the closing of a $96 million Series B financing. The financing was led by Aisling Capital with participation from founding investor Versant Ventures and existing investor New Enterprise Associates (NEA). Wilson Sonsini Goodrich & Rosati advised NEA in the transaction.

According to the press release, the financing will enable Monte Rosa to accelerate the growth of its pipeline, advance development candidates into the clinic, and bolster its platform capabilities to rationally design and develop small molecule degraders that hijack the body’s innate ability to degrade proteins. This approach will enable Monte Rosa to eradicate undruggable proteins that cause or drive the progression of genomically defined diseases intractable to standard care, including cancer. 

The Wilson Sonsini team advising NEA in the financing includes partner Dan Koeppen and associate Meg Burton. 

Please see Monte Rosa’s press release announcing the financing for more information.